University of Texas's MD Anderson Cancer Center: Ibrutinib With Chemoimmunotherapy Improved Progression-Free Survival for Newly Diagnosed Mantle Cell Lymphoma Patients
June 04, 2022
June 04, 2022
HOUSTON, Texas, June 4 (TNSjou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on June 3, 2022:
* * *
MD Anderson-led trial is first to study BTK inhibitor as front-line option for MCL
* * *
Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle c . . .
* * *
MD Anderson-led trial is first to study BTK inhibitor as front-line option for MCL
* * *
Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle c . . .